Navidea Biopharmaceuticals said it has signed up the first patient in a Phase III trial that will test the PET imaging agent NAV4694. The study will evaluate the safety and efficacy of the agent in identifying beta amyloid in end-of-life patients with and without dementia. The study, to eventually include 275 individuals, will compare imaging data during life with autopsy findings.

Related Summaries